BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36782152)

  • 41. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?
    Das S; Dasari A
    Curr Oncol Rep; 2021 Mar; 23(4):43. PubMed ID: 33719003
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gastroenteropancreatic neuroendocrine carcinoma in children and adolescents: a population-based study.
    Lin W; Zhu Z; Shang Y
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):4. PubMed ID: 38168014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    Wang SJ; Whitman J; Paciorek A; Le BK; Nakakura EK; Behr SC; Joseph N; Zhang L; Hope TA; Bergsland EK
    J Neuroendocrinol; 2023 Apr; 35(4):e13260. PubMed ID: 37002881
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
    Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
    Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
    Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
    JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
    Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
    Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
    Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
    Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients.
    Nguyen AH; O'Leary MP; De Andrade JP; Ituarte PG; Warner SG; Melstrom LG; Kessler J; Fong Y; Li D; Singh G
    Am J Surg; 2022 May; 223(5):939-944. PubMed ID: 34474917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
    Rustgi SD; Oh A; Yang JY; Kang D; Wolin E; Kong CY; Hur C; Kim MK
    BMC Cancer; 2021 May; 21(1):597. PubMed ID: 34030646
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymph Node Metastasis in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors.
    Martin JA; Warner RRP; Aronson A; Wisnivesky JP; Kim MK
    Pancreas; 2017 Oct; 46(9):1214-1218. PubMed ID: 28902794
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with
    Kane A; Thorpe MP; Morse MA; Howard BA; Oldan JD; Zhu J; Wong TZ; Petry NA; Reiman R; Borges-Neto S
    J Nucl Med; 2018 Nov; 59(11):1708-1713. PubMed ID: 29777005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
    Lau SC; Abdel-Rahman O; Cheung WY
    Med Oncol; 2018 Aug; 35(9):123. PubMed ID: 30078166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
    Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor.
    Grillo F; Albertelli M; Brisigotti MP; Borra T; Boschetti M; Fiocca R; Ferone D; Mastracci L
    Neuroendocrinology; 2016; 103(5):452-9. PubMed ID: 26337010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
    Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
    Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative anemia: impact on short- and long-term outcomes following curative-intent resection of gastroenteropancreatic neuroendocrine tumors.
    Xiang JX; Nan YL; He J; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Lv Y; Zhang XF; Pawlik TM
    J Gastrointest Surg; 2024 Jun; 28(6):852-859. PubMed ID: 38538480
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patterns of Lymph Node Metastasis and Optimal Surgical Strategy in Small (≤20 mm) Gastroenteropancreatic Neuroendocrine Tumors.
    Cai Y; Liu Z; Jiang L; Ma D; Zhou Z; Ju H; Zhu Y
    Front Endocrinol (Lausanne); 2022; 13():871830. PubMed ID: 35937823
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.